Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
AOD 9604 binds to beta-3 adrenergic receptors located on adipocytes (fat cells)
Key considerations for oral formulations: Convenient: Familiar to most patients and easily integrated into daily routines without clinic visits
The evidence base for tirzepatide as monotherapy is robust, with pivotal trials including SURMOUNT-1 demonstrating significant weight reduction in adults with obesity, and SURPASS trials establishing glycemic efficacy in type 2 diabetes
These include: Increased energy levels and reduced fatigue Improved memory, concentration, and mood Healthy red blood cell production Prevention of nerve damage Support for healthy skin, hair, and nails Boosted immune system function
US$ 28.41
US$ 29.71
US$ 24.19
US$ 24.48
US$ 25.51
US$ 20.60
